伊曲莫德在国内上市了吗

Etrasimod is a new oral selective sphingosine 1-phosphate (S1P) receptor modulator, mainly targeted at adults with moderately to severely active ulcerative colitis. The drug exerts anti-inflammatory effects by regulating lymphocyte migration and has been approved for marketing in many countries. This article will provide a detailed explanation of the domestic listing status, purchase channels, and medical insurance coverage of Itramod.

Is itrimod available on the domestic market?

As an innovative therapeutic drug, its domestic launch has attracted much attention. On February 19, 2024, the European Commission approved itrimod for the treatment of patients 16 years and older with moderately to severely active ulcerative colitis (UC).

Current domestic marketing status

As of now, itramod has not been officially approved for marketing in mainland China. The National Medical Products Administration (NMPA) is still in the review process and is expected to complete approval within the next few years.

Clinical Trial Progress

Itrimod has launched multiple Phase III clinical trials in China, involving patients with moderate to severe ulcerative colitis. These trial data will support its domestic marketing application.

Domestic patients still need to wait for official approval results, but they are expected to have access to this innovative treatment option in the future.

Is itramod easy to buy?

Before it is officially launched, it is very important for patients to understand how to obtain itramod.

Regular purchasing channels

Since it has not yet been launched in China, it is currently not possible to purchase Itrimod through regular hospital pharmacies or pharmacies. Patients need to be wary of products sold through informal channels to avoid purchasing counterfeit and substandard drugs.

Alternative acquisition methods

Some patients can obtain drugs at designated medical institutions through overseas purchase of drugs, or participate in domestic clinical trials. It is recommended that these methods be carried out under the guidance of professionals.

Notes on International Purchasing

Purchasing from overseas involves greater risks, including the inability to guarantee the quality of medicines and non-compliance with transportation conditions. Customs also imposes strict restrictions on the import of prescription drugs.

Patients should remain patient and wait for the drug to be officially launched before obtaining it through formal channels.

Is itrimod included in the national medical insurance?

The coverage of medical insurance directly affects the accessibility of the drug and the economic burden of patients.

Current medical insurance status

Itrimod has not yet been included in China’s national medical insurance catalog, mainly because the drug has not yet been officially launched in China.

Possibility of future inclusion

Referring to the medical insurance inclusion status of similar S1P receptor modulators, itrimod is expected to enter the national medical insurance directory through medical insurance negotiations within a few years after its launch.

It should be noted that Itrimod is contraindicated in patients with myocardial infarction, unstable angina, stroke, transient ischemic attack (TIA), decompensated heart failure requiring hospitalization, or grade III/IV heart failure within the past 6 months.